{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:45:54Z","timestamp":1787161554128,"version":"build-2736575974"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:00:00Z","timestamp":1552435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.00212","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T03:40:11Z","timestamp":1552448411000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":125,"title":["Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists"],"prefix":"10.3389","volume":"10","author":[{"given":"Tamara","family":"P\u00e9rez-Jeldres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Tyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thangaraj","family":"Karuppuchamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Yarur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaila","family":"Yeasmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Lundborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Rivera-Nieves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,13]]},"reference":[{"key":"B1","author":"Abbas","year":"","journal-title":"Cellular and Molecular Immunology. Chapter 3."},{"key":"B2","author":"Abbas","year":"","journal-title":"Cellular and Molecular Immunology. Chapter 7."},{"key":"B3","author":"Abbas","year":"","journal-title":"Cellular and Molecular Immunology. Chapter 10."},{"key":"B4","author":"Abbas","year":"","journal-title":"Cellular and Molecular Immunology. Chapter 15."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease.","volume":"361","author":"Abraham","year":"2009","journal-title":"New Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK\u2013STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects.","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/RHU.0000000000000663","article-title":"A case of series on patients on tofacitinib in combinaton with a biologic.","volume":"24","author":"Barroso","year":"2017","journal-title":"J. Clin. Rheumatol."},{"key":"B8","author":"Beattie","year":"2018","journal-title":"P069 TD-1473, a Novel, Potent, and Orally Administered, GI-Targeted, Pan-Janus Kinase (JAK) Inhibitor."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e1815","DOI":"10.1212\/WNL.0000000000005529","article-title":"Progressive multifocal leukoencephalopathy after fingolimod treatment.","volume":"90","author":"Berger","year":"2018","journal-title":"Neurology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.gtc.2017.05.015","article-title":"Janus kinase antagonists and other novel small molecules for the treatment of crohn\u2019s disease.","volume":"46","author":"Boland","year":"2017","journal-title":"Gastroenterol. Clin. North Am."},{"key":"B11","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/art.38974","article-title":"Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.","volume":"67","author":"Charles-Schoeman","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases.","volume":"57","author":"Clark","year":"2013","journal-title":"J. Med. Chem."},{"key":"B13","year":"","journal-title":"NCT01375179. A Multi-centre, Double-blind, Placebo Controlled, Parallel Group, Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of KRP203 in Subjects With Moderately Active Refractory Ulcerative Colitis."},{"key":"B14","year":"","journal-title":"NCT01563302. Phase 1\/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to PAtients with Advanced Cancers."},{"key":"B15","year":"","journal-title":"NCT02378688. Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn\u2019s Disease."},{"key":"B16","year":"","journal-title":"NCT02389790. Extension Study of MT-1303 in Subjects With Crohn\u2019s Disease."},{"key":"B17","year":"","journal-title":"NCT02535689. Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus"},{"key":"B18","year":"","journal-title":"NCT02818686. TD-1473 for Active Ulcerative Colitis (UC)."},{"key":"B19","year":"","journal-title":"NCT02819635. A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis (UC)."},{"key":"B20","year":"","journal-title":"NCT02914522. Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis (SELECTION1)."},{"key":"B21","year":"","journal-title":"NCT02914535. Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis (SELECTIONLTE)."},{"key":"B22","year":"","journal-title":"NCT02914600. Filgotinib in Long-Term Extension Study of Adults With Crohn\u2019s Disease (DIVERSITYLTE)"},{"key":"B23","year":"","journal-title":"NCT02958865. Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects with Moderate to Severe Ulcerative Colitis."},{"key":"B24","year":"","journal-title":"NCT03006068. A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis (UC)."},{"key":"B25","year":"","journal-title":"NCT03046056. Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn\u2019s Disease (SBCD)."},{"key":"B26","volume":"25","year":"","journal-title":"NCT03100942.Safety and Efficacy Study of Filgotinib, GS-9876 and Tirabrutinib in Adults With Active Sjogren\u2019s Syndrome"},{"key":"B27","year":"","journal-title":"NCT03345836. A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn\u2019s Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy."},{"key":"B28","year":"","journal-title":"NCT03345849. A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn\u2019s Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have."},{"key":"B29","year":"","journal-title":"NCT03395184. Study to Evaluate the Efficacy and Safety of Oral PF-06651600 And PF-06700841 In Subjects with Moderate to Severe Crohn\u2019s Disease."},{"key":"B30","year":"","journal-title":"NCT03624959. Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and\/or CYP3A."},{"key":"B31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40744-018-0097-3","article-title":"Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis.","volume":"5","author":"Cohen","year":"2018","journal-title":"Rheumatol. Ther."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00400","article-title":"Frontiers in drug research and development for inflammatory bowel disease.","volume":"8","author":"Curr\u00f2","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.4049\/jimmunol.178.4.2458","article-title":"FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells.","volume":"178","author":"Daniel","year":"2007","journal-title":"J. Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.1172\/JCI74188","article-title":"Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs.","volume":"124","author":"Degagn\u00e9","year":"2014","journal-title":"J. Clin. Invest."},{"key":"B35","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3892\/or.16.4.699","article-title":"The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice.","volume":"16","author":"Deguchi","year":"2006","journal-title":"Oncol. Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.clim.2008.08.018","article-title":"The effects of IL-6 on CD4 T cell responses.","volume":"130","author":"Dienz","year":"2009","journal-title":"Clin. Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/nm.3685","article-title":"Inhibiting Janus kinases to treat alopecia areata.","volume":"20","author":"Divito","year":"2014","journal-title":"Nat. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1124\/dmd.113.054940","article-title":"The pharmacokinetics, metabolism and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"B39","year":"2018","journal-title":"FDA. FDA Drug Safety Communication: FDA Warns About Cases of Rare Brain Infection with MS Drug Gilenya (fingolimod) in Two Patients With no Prior Exposure to Immunosuppressant Drugs."},{"key":"B40","author":"Feagan","year":"2017","journal-title":"P1272 - Endoscopic and Clinical Efficacy Demonstrated With Oral Ozanimod in Moderately to Severely Active Crohn\u2019s Disease. WCG at ACG."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40265-017-0755-8","article-title":"Advances in the development of janus kinase inhibitors in inflammatory bowel disease: future prospects.","volume":"77","author":"Flamant","year":"2017","journal-title":"Drugs"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.12703\/P6-109","article-title":"S1P signaling: new therapies and opportunities.","volume":"6","author":"Gonzalez-Cabrera","year":"2014","journal-title":"F1000 Prime Rep."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy189","article-title":"Clinical pharmacology in adult and pediatric inflammatory bowel disease.","author":"Hemperly","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1586\/14737175.8.5.699","article-title":"FTY720 (fingolimod) for relapsing multiple sclerosis.","volume":"8","author":"Horga","year":"2008","journal-title":"Expert Rev. Neurother."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMc1412997","article-title":"Remission of recalcitrant dermatomyositis treated with ruxolitinib.","volume":"371","author":"Hornung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/283617","article-title":"JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.","volume":"2014","author":"Hsu","year":"2014","journal-title":"J. Immunol. Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.immuni.2009.09.002","article-title":"Cross-regulation of signaling and immune responses by IFN-\u03b3 and STAT1.","volume":"31","author":"Hu","year":"2009","journal-title":"Immunity"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1096\/fj.201600394R","article-title":"Sphingosine-1-phosphate phosphatase 2 promotes disruption of mucosal integrity and contributes to ulcerative colitis in mice and humans.","volume":"30","author":"Huang","year":"2016","journal-title":"FASEB J."},{"key":"B49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pharmthera.2017.11.001","article-title":"The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: recent findings and new perspectives.","volume":"185","author":"Huwiler","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1097\/MIB.0000000000000495","article-title":"Altered STAT4 isoform expression in patients with inflammatory bowel disease.","volume":"21","author":"Jabeen","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/1947601910397187","article-title":"JAK\/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.","volume":"1","author":"Jatiani","year":"2010","journal-title":"Genes Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-018-0752-2","article-title":"Cardiovascular safety of biologics and JAK inhibitors in patients with rheumatoid arthritis.","volume":"20","author":"Kang","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"B53","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1182\/blood-2009-04-216390","article-title":"The transcription factors STAT5A\/B regulate GM-CSF-mediated granulopoiesis.","volume":"114","author":"Kimura","year":"2009","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Practice parameters committee of the american college of gastroenterology.","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/jcb.20097","article-title":"Generation and metabolism of bioactive sphingosine-1-phosphate.","volume":"92","author":"Le Stunff","year":"2004","journal-title":"J. Cell. Biochem."},{"key":"B56","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2015.06.045","article-title":"Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate.","volume":"73","author":"Levy","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"A39","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Tofacitinib, an oral Janus Kinase inhibitor, in the treatment of ulcerative colitis: open-label, long-term extension study.","volume":"5","author":"Lichtenstein","year":"2017","journal-title":"United Eur. Gastroenterol. J."},{"key":"B58","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of crohn\u2019s disease in adults.","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.","volume":"77","author":"Liu","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis.","author":"Mahadevan","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrd4088","article-title":"Therapeutic modulators of STAT signalling for human diseases.","volume":"12","author":"Miklossy","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"B62","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/00054725-200405000-00002","article-title":"Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis.","volume":"10","author":"Mizushima","year":"2004","journal-title":"Inflamm. Bowel Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0792-2","article-title":"Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.","volume":"17","author":"Montor","year":"2018","journal-title":"Mol. Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1194\/jlr.M034108","article-title":"S1P1 localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity.","volume":"54","author":"Montrose","year":"2013","journal-title":"J. Lipid Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1080\/21645515.2015.1057363","article-title":"Small molecule drugs with immunomodulatory effects in cancer.","volume":"11","author":"Murphy","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"B66","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/gutjnl-2016-312912","article-title":"Next generation of small molecules in inflammatory bowel disease.","volume":"66","author":"Olivera","year":"2016","journal-title":"Gut"},{"key":"B67","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/1744666X.2017.1291342","article-title":"JAK inhibition in inflammatory bowel disease.","volume":"13","author":"Olivera","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms.","volume":"91","author":"Ord\u00e1s","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/1744666X.2017.1343668","article-title":"New treatment strategies for ulcerative colitis.","volume":"13","author":"Panes","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials.","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"key":"B71","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4062\/biomolther.2016.160","article-title":"Sphingosine 1-phosphate receptor modulators and drug discovery.","volume":"25","author":"Park","year":"2017","journal-title":"Biomol. Ther."},{"key":"B72","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMct1101691","article-title":"Fingolimod for multiple sclerosis.","volume":"366","author":"Pelletier","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy269","article-title":"Cell trafficking interference in inflammatory bowel disease: therapeutic interventions based on pathogenesis concepts.","author":"Perez-Jeldres","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1096\/fj.02-1038com","article-title":"The sphingosine kinase 1\/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha.","volume":"17","author":"Pettus","year":"2003","journal-title":"FASEB J."},{"key":"B75","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease.","volume":"16","author":"Peyrin-Biroulet","year":"","journal-title":"Autoimmun. Rev."},{"key":"B76","author":"Peyrin-Biroulet","year":"","journal-title":"Safety, Tolerability and Lymphocyte-Lowering Properties of Etrasimod (APD334), an Oral, Potent, Next-Generation, Selective S1P Receptor Modulator, After Dose Escalation in Healthy Volunteer."},{"key":"B77","year":"2018","journal-title":"Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis."},{"key":"B78","first-page":"S285","article-title":"P372. A multicentre, double-blind, placebo-controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of the S1P receptor modulator KRP203 in subjects with moderately active refractory ulcerative colitis.","volume":"10","author":"Radeke","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s10620-011-1628-8","article-title":"Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12\/23p40 in a TNBS-induced Crohn\u2019s disease model.","volume":"56","author":"Radi","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"B80","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-397176-0.00005-4","article-title":"\u201cSimilarities and differences in the discovery and use of biopharmaceuticals and small-molecule chemotherapeutics,\u201d in","author":"Samanen","year":"2013","journal-title":"Introduction to Biological and Small Molecule Drug Research and Development: Theory and Case Studies"},{"key":"B81","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/jcb.20127","article-title":"Structural and functional characteristics of S1P receptors.","volume":"92","author":"Sanchez","year":"2004","journal-title":"J. Cell. Biochem."},{"key":"B82","author":"Sandborn","year":"","journal-title":"The Intestinally Restricted, Orally Administered, Pan-Jak Inhibitor TD-1473 Demonstrate Favorable Safety, Tolerability, Pharmacokinetics, and Signal for Clinical Activity in Subjects With Moderately-to-Severely Active Ulcerative Colitis."},{"key":"B83","doi-asserted-by":"publisher","first-page":"S1308","DOI":"10.1016\/S0016-5085(17)34357-3","article-title":"Safety and efficacy of ABT-494 (Upadacitinib), an oral jak1 inhibitor, as induction therapy in patients with crohn\u2019s disease: results from Celest.","volume":"152","author":"Sandborn","year":"","journal-title":"Gastroenterology"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis.","volume":"374","author":"Sandborn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B85","author":"Sandborn","year":"","journal-title":"Efficacy and Safety of Upadacitinib as an Induction Therapy For Patients With Moderately-to Severely Active Ulcerative Colitis: Data From the Phase 2B Study U-ACHIEVE."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A phase 2 study of Tofacitinib, an oral janus kinase inhibitor, inpatients with crohn\u2019s disease.","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis.","volume":"376","author":"Sandborn","year":"","journal-title":"N. Engl. J. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.","volume":"367","author":"Sandborn","year":"2012","journal-title":"New Engl. J. Med."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy085","article-title":"Peficitinib, an oral janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomized, phase 2 study.","author":"Sands","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"B90","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity.","volume":"173","author":"Scott","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"B92","year":"2018","journal-title":"My 2 Cents On the Ozanimod Saga."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14092","article-title":"Amelioration of colitis through blocking lymphocytes entry to Peyer\u2019s patches by sphingosine-1-phosphate lyase inhibitor.","author":"Shirakabe","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1096\/fj.08-118109","article-title":"A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis.","volume":"23","author":"Snider","year":"2009","journal-title":"FASEB J."},{"key":"B95","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.pharmthera.2018.07.003","article-title":"Targeting JAK-STAT signal transduction in IBD.","volume":"192","author":"Soendergaard","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1002\/art.40186","article-title":"Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective Janus kinase 1 inhibitor, after short-term treatment of rheumatoid arthritis: results of two randomized Phase IIA trials.","volume":"69","author":"Vanhoutte","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","article-title":"Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors.","volume":"41","author":"Verden","year":"2018","journal-title":"Drug Saf."},{"key":"B98","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.","volume":"389","author":"Vermeire","year":"","journal-title":"Lancet"},{"key":"B99","first-page":"A1","article-title":"Effect of disease duration and location on clinical remission in Crohn\u2019s disease patients treated with Filgotinib, a selective JAK1 inhibitor: post-hoc analysis from the phase 2 FITZROY study.","volume":"5","author":"Vermeire","year":"","journal-title":"United Eur. Gastroenterol. J."},{"key":"B100","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4049\/jimmunol.1401867","article-title":"Mechanisms of Jak\/STAT signaling in immunity and disease.","volume":"194","author":"Villarino","year":"2015","journal-title":"J. Immunol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system.","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1111\/apt.14669","article-title":"Review article: novel oral-targeted therapies in inflammatory bowel disease.","volume":"47","author":"White","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B103","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease.","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3390\/ijms1804074","article-title":"Sphingosine-1-phosphate metabolism and its role in the development of inflammatory bowel disease.","volume":"18","author":"Wollny","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1097\/MIB.0000000000000380","article-title":"Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases.","volume":"21","author":"Yarur","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1161\/CIRCULATIONAHA.117.030423","article-title":"Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis.","volume":"137","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"B107","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/ni1488","article-title":"IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways.","volume":"8","author":"Zhou","year":"2007","journal-title":"Nat. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00212\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T03:40:15Z","timestamp":1552448415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00212\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,13]]},"references-count":107,"alternative-id":["10.3389\/fphar.2019.00212"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.00212","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,13]]},"article-number":"212"}}